BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24791889)

  • 1. Prostate cancer antigen 3 test for prostate biopsy decision: a systematic review and meta analysis.
    Luo Y; Gou X; Huang P; Mou C
    Chin Med J (Engl); 2014; 127(9):1768-74. PubMed ID: 24791889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and meta-analysis].
    Ruiz-Aragón J; Márquez-Peláez S
    Actas Urol Esp; 2010 Apr; 34(4):346-55. PubMed ID: 20470697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: a systematic review and meta-analysis.
    Luo Y; Gou X; Huang P; Mou C
    Asian J Androl; 2014; 16(3):487-92. PubMed ID: 24713827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
    Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
    Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis.
    Cui Y; Cao W; Li Q; Shen H; Liu C; Deng J; Xu J; Shao Q
    Sci Rep; 2016 May; 6():25776. PubMed ID: 27161545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer.
    Bradley LA; Palomaki GE; Gutman S; Samson D; Aronson N
    J Urol; 2013 Aug; 190(2):389-98. PubMed ID: 23545099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
    Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
    Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of urine prostate cancer antigen 3 test using a cutoff value of 35 μg/L in patients with prostate cancer.
    Hu B; Yang H; Yang H
    Tumour Biol; 2014 Sep; 35(9):8573-80. PubMed ID: 24863945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.
    Scattoni V; Lazzeri M; Lughezzani G; De Luca S; Passera R; Bollito E; Randone D; Abdollah F; Capitanio U; Larcher A; Lista G; Gadda GM; Bini V; Montorsi F; Guazzoni G
    J Urol; 2013 Aug; 190(2):496-501. PubMed ID: 23466239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis accuracy of PCA3 level in patients with prostate cancer: a systematic review with meta-analysis.
    Qin Z; Yao J; Xu L; Xu Z; Ge Y; Zhou L; Zhao F; Jia R
    Int Braz J Urol; 2020; 46(5):691-704. PubMed ID: 31961625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
    Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J
    Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
    Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
    BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
    De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
    Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects.
    Schmid M; Hansen J; Chun FK
    Adv Exp Med Biol; 2015; 867():277-89. PubMed ID: 26530372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer.
    Roberts MJ; Chow CW; Schirra HJ; Richards R; Buck M; Selth LA; Doi SA; Samaratunga H; Perry-Keene J; Payton D; Yaxley J; Lavin MF; Gardiner RA
    Prostate; 2015 Apr; 75(5):539-49. PubMed ID: 25597828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
    Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
    Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging biomarkers in the detection and prognosis of prostate cancer.
    Filella X; Foj L
    Clin Chem Lab Med; 2015 Jun; 53(7):963-73. PubMed ID: 25581761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program.
    Rubio-Briones J; Casanova J; Dumont R; Rubio L; Fernandez-Serra A; Casanova-Salas I; Domínguez-Escrig J; Ramírez-Backhaus M; Collado A; Gómez-Ferrer A; Iborra I; Monrós JL; Ricós JV; Solsona E; Salas D; Martínez F; Lopez-Guerrero JA
    Actas Urol Esp; 2014 May; 38(4):217-23. PubMed ID: 24169211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.